Aquestive 报告 Anaphylm 人体因素与药代动力学研究结果呈阳性

该公司宣布其 Anaphylm 舌下膜的人体因素验证研究和药代动力学研究取得积极结果。这些数据支持计划向 FDA 重新提交 NDA，用于治疗 1 型过敏反应，包括过敏性休克。

关键事实

申报时间: 2026年8月10日 11:05
事件: 顶线结果
方向: 积极
公司: AQSTAquestive
资产: epinephrine
来源: SEC 8-K
可信度: 有来源
日历: 试验结果公布 · 2026年7月1日 · 积极

来源摘录

aqst-20260810 0001398733 false 0001398733 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2026 Aquestive Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-38599 82-3827296 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 30 Technology Drive Warren , NJ 07059 ( 908 ) 941-1900 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Not Applicable (Former name or former address, if changed since last report) ______________________

SEC 8-K